FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247993854> ?p ?o ?g. }

• W4247993854 abstract "<sec> <title>BACKGROUND</title> Diabetic kidney disease (DKD) is one of the main complications of type 2 diabetes mellitus (T2DM). DKD is a known risk factor for end-stage renal disease, cardiovascular disease, and all-cause death. Effective intervention for early-stage DKD is vital to slowing down the progression of kidney disease and improve prognoses. Mobile health (mHealth) is reportedly effective in supporting patients’ self-care and improving glycemic control, but the impact of mHealth on DKD has yet to be shown. </sec> <sec> <title>OBJECTIVE</title> The purpose of this study is to evaluate the efficacy of standard therapy with the addition of a self-management support system, DialBetesPlus, in patients with DKD and microalbuminuria. </sec> <sec> <title>METHODS</title> This study is a prospective, randomized, open-label, multicenter clinical trial. The target population consists of 160 patients diagnosed with T2DM accompanied by microalbuminuria. We randomly assigned the patients to 2 groups—the intervention group using DialBetesPlus in addition to conventional therapy and the control group using conventional therapy alone. DialBetesPlus is a smartphone application that supports patients’ self-management of T2DM. The study period was 12 months, with a follow-up survey at 18 months. The primary outcome was a change in albuminuria levels at 12 months. Secondary outcomes included changes in physical parameters, blood test results (glycemic control, renal function, and lipid metabolism), lifestyle habits, self-management scores, medication therapy, and quality of life. </sec> <sec> <title>RESULTS</title> The study was approved in April 2018. We began recruiting patients in July 2018 and completed recruiting in August 2019. The final 18-month follow-up was conducted in March 2021. We recruited 159 patients and randomly allocated 70 into the intervention group and 61 into the control group, with 28 exclusions due to withdrawal of consent, refusal to continue, or ineligibility. The first results are expected to be available in 2021. </sec> <sec> <title>CONCLUSIONS</title> This is the first randomized controlled trial assessing the efficacy of mHealth on early-stage DKD. We expect that albuminuria levels will decrease significantly in the intervention group due to improved glycemic control with ameliorated self-care behaviors. </sec> <sec> <title>CLINICALTRIAL</title> UMIN-CTR UMIN000033261; https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000037924 </sec> <sec> <title>INTERNATIONAL REGISTERED REPORT</title> DERR1-10.2196/31061 </sec>" @default.
• W4247993854 created "2022-05-12" @default.
• W4247993854 creator A5003380681 @default.
• W4247993854 creator A5008359331 @default.
• W4247993854 creator A5010378055 @default.
• W4247993854 creator A5011872680 @default.
• W4247993854 creator A5014376109 @default.
• W4247993854 creator A5015785069 @default.
• W4247993854 creator A5019024662 @default.
• W4247993854 creator A5025069327 @default.
• W4247993854 creator A5028819689 @default.
• W4247993854 creator A5028959989 @default.
• W4247993854 creator A5029747116 @default.
• W4247993854 creator A5036113498 @default.
• W4247993854 creator A5040548657 @default.
• W4247993854 creator A5043931842 @default.
• W4247993854 creator A5048273973 @default.
• W4247993854 creator A5049632432 @default.
• W4247993854 creator A5052636056 @default.
• W4247993854 creator A5054417536 @default.
• W4247993854 creator A5058529912 @default.
• W4247993854 creator A5061386169 @default.
• W4247993854 creator A5063566174 @default.
• W4247993854 creator A5078504986 @default.
• W4247993854 creator A5083201653 @default.
• W4247993854 creator A5085969573 @default.
• W4247993854 creator A5088387334 @default.
• W4247993854 date "2021-06-08" @default.
• W4247993854 modified "2023-10-12" @default.
• W4247993854 title "Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial (Preprint)" @default.
• W4247993854 cites W1992089240 @default.
• W4247993854 cites W2053091007 @default.
• W4247993854 cites W2077615743 @default.
• W4247993854 cites W2079193114 @default.
• W4247993854 cites W2089374143 @default.
• W4247993854 cites W2100476420 @default.
• W4247993854 cites W2112457187 @default.
• W4247993854 cites W2118286022 @default.
• W4247993854 cites W2130508358 @default.
• W4247993854 cites W2133746099 @default.
• W4247993854 cites W2139394550 @default.
• W4247993854 cites W2157677774 @default.
• W4247993854 cites W2168261002 @default.
• W4247993854 cites W2168602960 @default.
• W4247993854 cites W2178942812 @default.
• W4247993854 cites W2295174967 @default.
• W4247993854 cites W2489583246 @default.
• W4247993854 cites W2512638651 @default.
• W4247993854 cites W2552511422 @default.
• W4247993854 cites W2568422350 @default.
• W4247993854 cites W2592184816 @default.
• W4247993854 cites W2592651846 @default.
• W4247993854 cites W2615714795 @default.
• W4247993854 cites W2619251630 @default.
• W4247993854 cites W2626446274 @default.
• W4247993854 cites W2752707491 @default.
• W4247993854 cites W2779028451 @default.
• W4247993854 cites W2906810961 @default.
• W4247993854 cites W4248736820 @default.
• W4247993854 doi "https://doi.org/10.2196/preprints.31061" @default.
• W4247993854 hasPublicationYear "2021" @default.
• W4247993854 type Work @default.
• W4247993854 citedByCount "0" @default.
• W4247993854 crossrefType "posted-content" @default.
• W4247993854 hasAuthorship W4247993854A5003380681 @default.
• W4247993854 hasAuthorship W4247993854A5008359331 @default.
• W4247993854 hasAuthorship W4247993854A5010378055 @default.
• W4247993854 hasAuthorship W4247993854A5011872680 @default.
• W4247993854 hasAuthorship W4247993854A5014376109 @default.
• W4247993854 hasAuthorship W4247993854A5015785069 @default.
• W4247993854 hasAuthorship W4247993854A5019024662 @default.
• W4247993854 hasAuthorship W4247993854A5025069327 @default.
• W4247993854 hasAuthorship W4247993854A5028819689 @default.
• W4247993854 hasAuthorship W4247993854A5028959989 @default.
• W4247993854 hasAuthorship W4247993854A5029747116 @default.
• W4247993854 hasAuthorship W4247993854A5036113498 @default.
• W4247993854 hasAuthorship W4247993854A5040548657 @default.
• W4247993854 hasAuthorship W4247993854A5043931842 @default.
• W4247993854 hasAuthorship W4247993854A5048273973 @default.
• W4247993854 hasAuthorship W4247993854A5049632432 @default.
• W4247993854 hasAuthorship W4247993854A5052636056 @default.
• W4247993854 hasAuthorship W4247993854A5054417536 @default.
• W4247993854 hasAuthorship W4247993854A5058529912 @default.
• W4247993854 hasAuthorship W4247993854A5061386169 @default.
• W4247993854 hasAuthorship W4247993854A5063566174 @default.
• W4247993854 hasAuthorship W4247993854A5078504986 @default.
• W4247993854 hasAuthorship W4247993854A5083201653 @default.
• W4247993854 hasAuthorship W4247993854A5085969573 @default.
• W4247993854 hasAuthorship W4247993854A5088387334 @default.
• W4247993854 hasBestOaLocation W42479938542 @default.
• W4247993854 hasConcept C126322002 @default.
• W4247993854 hasConcept C134018914 @default.
• W4247993854 hasConcept C168563851 @default.
• W4247993854 hasConcept C1862650 @default.
• W4247993854 hasConcept C2776174234 @default.
• W4247993854 hasConcept C2778653478 @default.
• W4247993854 hasConcept C2779134260 @default.
• W4247993854 hasConcept C2780473172 @default.
• W4247993854 hasConcept C2781203188 @default.
• W4247993854 hasConcept C2908647359 @default.

• next